F-FDG) were proposed as complementary biochemical probes to characterize hepatocellular carcinoma before undergoing the administration of 90 Y-labeled glass microspheres, as the more aggressive hepatocellular lesions are generally 18 F-FDG-avid, while the more differentiated ones can be visualized using 11 C-acetate. A growing amount of scientific data concerning 90 Yradioembolization in hepatocellular carcinoma has demonstrated its significant impact on outcomes [2] . To date,
90
Yradioembolization represents a well-standardized procedure in which two commercially available devices (glass or resin microspheres) can be used. In this scenario, the study performed by Ho and coworkers provides an opportunity to elaborate this innovative therapeutic approach from a theranostic perspective. The theranostic approach is a typical feature of nuclear medicine in which diagnostic imaging and therapy are often performed using the same molecules labeled with different radionuclides [3] . By extension, theranostics represent a combination of diagnostic and target therapy in order to achieve a personalized approach for every patient's needs and characteristics.
In this regard, the authors correlated the biological aggressiveness of hepatocellular carcinoma, determined by its affinity for Yglass microspheres. In this context, PET imaging with a specific molecular probe was used to define the most appropriate therapeutic approach. However, it has to be pointed out that acetate is labeled with 11 C with a short 20-min half-life, limiting the use of this radiopharmaceutical only to PET-centers with on-site cyclotron. To overcome these drawbacks, 18 Fcholine, a surrogate biomarker of membrane lipid synthesis, has been introduced for the PET imaging of welldifferentiated hepatocellular carcinoma, with a sensitivity ranging from 63 to 100% [4] . In our experience, the complementary use of 18 F-FDG and 18 F-choline may be particularly useful for the PET evaluation of plurifocal hepatocellular carcinoma before 90 Y-radioembolization, as hepatic nodules within the same patient may present different grade of biological aggressiveness (Fig. 1) .
It should be noted that Ho et al. [1] defined the response to 90 Y-treatment as a decrease in metabolic tumor volume calculated on the PET-CT performed 2 months after the procedure. Which the best time point and imaging method are to assess tumors following therapy with 90 Y-microspheres is still under debate. Nevertheless, several published papers suggested that an early metabolic evaluation of hepatic tumors after locoregional treatments can be feasible as soon as 1 month after the procedure [5] . In a recent report from our group, the decrease in total lesion glycolysis (metabolic tumor volume × SUVmean) calculated on 18 F-FDG PET at baseline and 1 month after 90 Y-radioembolization resulted in a significant prognostic factor in patients affected by poorly differentiated hepatocellular carcinoma and portal vein tumor thrombosis [6] . We believe that a metabolic evaluation of hepatic tumors after therapy with 90 Y-microspheres can be performed as early as at 1 month after therapy, in order to readily identify nonresponders patients who would benefit from other therapeutic options.
It would be worthwhile to further investigate how much the complementary use of different PET molecular probes (i.e., 
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